Reuters: Regulatory News: Merck says key Vytorin study cleared to continue

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Merck says key Vytorin study cleared to continue Mar 28th 2012, 12:01 March 28 | Wed Mar 28, 2012 8:01am EDT March 28 (Reuters) - A closely watched study of Merck & Co Inc's Vytorin cholesterol treatment was cleared by safety monitors to continue, the drugmaker said on Wednesday. Wall Street has been eagerly anticipating the interim look at data from the 18,000-patient Improve-It study to see whether Vytorin is helping improve heart outcomes. However, Merck did not release any data on Wednesday, saying it remained blinded to the results of the interim analysis. It said only that the safety monitors overseeing the trial recommended it continue without change and that they plan to review the data again in about nine months.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions